TrialThe Lancet. Oncology2018
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
Sandra P D'Angelo et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
476 papers cite itlatest 60 shown
this paperpooled ittrialcites it